Ubrogepant 100 mg achieves 70% headache resolution in acute migraine patients within 2 hours
Background
Globally, migraine imposes a substantial health burden, with prevalence rates in Saudi Arabia exceeding the global average. Effective acute management is critical, yet conventional treatments often present challenges. Calcitonin gene-related peptide (CGRP) receptor antagonists like ubrogepant offer a targeted mechanism by blocking the CGRP receptor, a key mediator in migraine pathophysiology. While ubrogepant's efficacy is established in diverse populations, localized data, particularly from Saudi Arabia, has been lacking, creating a gap in understanding its real-world performance in this specific demographic.
Study Design
This retrospective case series evaluated Ubrogepant 100 mg for acute migraine management among patients in Hail City, Saudi Arabia. The study included 27 patients identified via electronic medical records who had been prescribed the compound. Participants were contacted through patient portals, phone, or clinic visits to complete a 15-item open-ended questionnaire. The survey specifically assessed treatment response, safety, and tolerability of Ubrogepant 100 mg as the primary endpoints, without a dedicated control arm.
Results
Among the 27 migraine patients treated with Ubrogepant 100 mg, a significant majority experienced rapid and effective relief. Nearly 70% of patients achieved complete headache resolution within 2 hours of administration. Furthermore, 80% reported significant migraine relief within 1.5 hours. Functional disability scores showed a statistically significant improvement (P = .001), indicating a positive impact on daily activities. Associated migraine symptoms, including photophobia and nausea, also declined. Regarding safety, nearly half (48%) of patients experienced mild side effects, predominantly fatigue, while more than half reported no adverse events. This suggests a favorable tolerability profile for the compound. The findings underscore the rapid action and overall positive patient experience with this CGRP receptor antagonist.
Nearly 70% of patients achieved complete headache resolution within 2 hours of taking Ubrogepant 100 mg.
Key Findings
- Nearly 70% of patients achieved complete headache resolution within 2 hours of taking Ubrogepant.
- 80% of patients experienced significant migraine relief within 1.5 hours.
- Functional disability scores significantly improved (P = .001) following treatment.
- Associated symptoms like photophobia and nausea also declined.
- Over half of patients reported no adverse events, with 48% experiencing only mild side effects, primarily fatigue.
Why It Matters
This study provides crucial real-world evidence supporting Ubrogepant 100 mg as an effective and well-tolerated acute migraine treatment, particularly for patients in Saudi Arabia. The rapid onset of action, with 70% achieving headache resolution within 2 hours, is a significant practical takeaway for clinicians and individuals seeking quick relief. This data reinforces Ubrogepant's utility as a viable first-line or rescue option for acute migraine attacks. The high tolerability, with over half reporting no side effects, suggests it can be integrated into existing acute migraine protocols with confidence, potentially improving patient adherence and overall quality of life. While a retrospective case series, these findings offer valuable insights into its clinical translation and practical application.
ubrogepant
migraine
acute-migraine
cgrp-antagonist
saudi-arabia
case-series